Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 2013 Jul;69(1):61-5
Date
03/05/2013Pubmed ID
23453243DOI
10.1016/j.jaad.2012.12.975Scopus ID
2-s2.0-84879089345 (requires institutional sign-in at Scopus site) 30 CitationsAbstract
BACKGROUND: The use of many of the standard skin-directed mycosis fungoides (MF) therapies on facial skin may be limited by site-specific increased risks of side effects, excessive inflammation, and ocular toxicity.
OBJECTIVE: Our study aimed to describe the levels of erythema, scale, and induration of facial lesions in MF before and after low-dose high-dose-rate surface applicator brachytherapy and to examine the overall clinical response to brachytherapy.
METHODS: A total of 23 facial MF lesions in 10 patients were treated with high-dose-rate brachytherapy doses of 4 Gy per session for a total of 2 fractions at our multidisciplinary cutaneous oncology clinic between August 17, 2009, and March 12, 2012.
RESULTS: In all 23 lesions, dramatic clinical improvement was observed. Patients were followed up for a median of 6.3 months. No recurrences were reported in the follow-up period.
LIMITATIONS: Long-term follow-up is lacking. Reassessment of all included patients at annual intervals for a period of at least 5 years is the authors' goal.
CONCLUSION: Low-dose high-dose-rate brachytherapy using custom-made surface molds is a highly efficacious therapy in the treatment of facial lesions in MF.
Author List
DeSimone JA, Guenova E, Carter JB, Chaney KS, Aldridge JR, Noell CM, Dorosario AA, Hansen JL, Kupper TS, Devlin PMAuthor
Keri S. Chaney MD Assistant Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAged, 80 and over
Brachytherapy
Dose-Response Relationship, Radiation
Erythema
Facial Neoplasms
Female
Humans
Male
Middle Aged
Mycosis Fungoides
Radiotherapy
Radiotherapy Dosage
Skin Neoplasms
Treatment Outcome
